Chk2 Antibody (pThr68): ATTO 390

Polyclonal

Blue Ice or 4ºC. All orders received in North America by 12:00 PM PST Monday to Thursday will usually be shipped out on the same day. North American customers will typically receive their orders within 1-2 business days. All shipments are F.O.B. from point of shipment, pre-paid and added to the invoice. Freight charges include but not limited to: priority service and packaging materials.Products are shipped with “cold packs” in insulated containers. There is a charge for this packaging and for the shipping costs via FedEx. Please inspect packages immediately upon receipt and inform Labscoop Customer Support of any shortage or damage within 48 hours of receipt. We can only accept returns after we have given prior authorization and issued specific shipping instructions. If a customer wishes to use their own FedEx account number please indicate this on the purchase order or during checkout.

Canada

WB, AM

https://www.ncbi.nlm.nih.gov/gene/11200

NP_009125

Non-hazardous

Non-hazardous

Not for use in humans. Not for use in diagnostics or therapeutics. For in vitro research use only.

WB (1:250); optimal dilutions for assays should be determined by the user.

Rabbit

Human

ATTO 390

Peptide Affinity Purified

ISO 9001:2015

Chk2 (pThr68)

A phospho-specific peptide corresponding to residues surrounding Thr68 of human Chk2 (AA65-71)

Detects 60.915 kDa.

PBS pH7.4, 50% glycerol, 0.025% Thimerosal *Storage buffer may change when conjugated

https://antibodyregistry.org/search.php?q=AB_2707518

Nucleus

Chk2 is a protein kinase involved in cell cycle arrest in response to DNA damage. CHK2 is activated through phosphorylation by ATM and ATR at T68. Activated CHK2 phosphorylates and inhibits CDC25 a dual-specificity phosphatase required for progression through the cell cycle. CHK2 further causes cell cycle earrest through activation of a DNA repair protein BRCA1 and apoptosis factor PML. The role of CHK2 in the development of cancer is in a primarily tumour suppressor role through causing cell cycle arrest. It has been observed that inhibition of CHK2 through mutations in the regulatory FHA domain has been observed in low frequency in osteosarcomas and cancers of the ovary, lung and vulva. Another mutation, "1100delC" has been commonly found in breast cancers.

Cell Signaling | Epigenetics and Nuclear Signaling | DNA/RNA | DNA Damage and Repair | Chk1 / Chk2 | Cancer | Cell Cycle | Cell Signaling | Protein Phosphorylation

Cds1 homolog Antibody, Checkpoint kinase 2 Antibody, CHEK 2 Antibody, CHK2 checkpoint homolog Antibody, CHK2_HUMAN Antibody, hCds1 Antibody, LFS 2 Antibody, PP1425 Antibody, RAD 53 Antibody, Serine/threonine protein kinase Chk2 Antibody